Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Anthony Lombardo, interim chief executive officer, will present a company overview at the Cantor Fitzgerald Global Healthcare Conference being held Sept. 25-27, 2017 in New York. The conference will feature more than 200 innovative industry leaders from public and private companies for an in-depth discussion of the developments and trends shaping biotechnology, specialty pharmaceuticals, medical technology, healthcare facilities and services, and life sciences tools and diagnostics.

Event: Cantor Fitzgerald Global Healthcare Conference

Presentation Date: Monday, Sept. 25, 2017

Presentation Time: 8:30 a.m. EDT

Location: InterContinental New York Barclay Hotel, New York

Lombardo has nearly 30 years of leadership experience in the life sciences industry with a proven track record of helping global companies achieve significant growth. Honored by the American College of Radiology and the Society of Abdominal Radiology for his years of service to the clinical community, he currently serves as chairman of the advisory board of Morristown Medical Center, a part of Atlantic Health System Hospitals.

About Advaxis, Inc.

Advaxis, Inc., located in Princeton N.J., is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and pre-clinical development: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube.

Advaxis Forward-Looking Statement

This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov.

Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law.

You are cautioned not to place undue reliance on any forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170918005383/en/

Company:
Advaxis, Inc.
Noelle Heber, 609-250-7575
Sr. Director Corporate Communications and Government Affairs
[email protected]
or
Media:
Stern Strategy Group
Brian Hyland, 908-325-3891
[email protected]

Source: Advaxis, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• RenovoRx regains Nasdaq minimum bid price compliance
• Gossamer Bio raises up to $250M in private placement for PAH drug
• CoStar Group acquires Zonda for $800M, adding new home data